Better Care for PFAS Patients Act of 2026
Sponsored By: Representative Rep. Dexter, Maxine [D-OR-3]
Introduced
Summary
Federally coordinated clinical guidance on per- and polyfluoroalkyl substances (PFAS) health effects. It would require the Agency for Toxic Substances and Disease Registry (ATSDR) to contract with the National Academies of Sciences, Engineering, and Medicine to assess PFAS health effects, issue initial clinical recommendations within 2 years, and update guidance at least every 5 years while posting and disseminating that guidance to state and local public health authorities and health care professionals.
Show full summary
- Families: PFAS-exposed families would get clearer clinical recommendations on testing and follow-up based on regular scientific assessments.
- Health care professionals: Clinicians would have ATSDR-posted, evidence-based recommendations to help identify PFAS-linked health effects and guide patient care.
- State and local public health agencies: Officials would receive consistent guidance to inform local surveillance and community health responses.
- PFAS-exposed communities: The contracting entity must solicit input from affected communities about exposure, testing, and clinical follow-up to shape recommendations.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Clinical guidance for PFAS exposure
If enacted, the bill would require the Director of the Agency for Toxic Substances and Disease Registry (ATSDR) to enter into an agreement with the National Academies or a similar group within 60 days of enactment. The contracted group would assess PFAS health effects measurable in people and must finish an initial assessment and recommendations within 2 years after the agreement. The Director would issue up-to-date clinical guidance and post it on ATSDR's public website and share it with State and local public health authorities and appropriate health care professionals not later than 5 years after the agreement. The assessments and guidance would be updated at least every 5 years or more often if needed, and the contracted group would engage PFAS-exposed communities to get input about testing, exposure, and clinical follow-up.
Free Policy Watch
You just read the policy. Now see what it costs you.
Pick a topic. PRIA runs your household against live legislation and sends you a free personalized readout.
Pick a topic to get started
Sponsors & CoSponsors
Sponsor
Rep. Dexter, Maxine [D-OR-3]
OR • D
Cosponsors
Rep. Lawler, Michael [R-NY-17]
NY • R
Sponsored 1/8/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in